Villageatlakepark Gatehouse Portal, Leyland Daf 45 Cab For Sale, Congressional Country Club Membership Application, Streamelements Not Showing Bttv Emotes, Eddie Van Halen Will And Testament, Articles P

Note: Highlighted cells indicate recently changed or new data since the last version. The VIS Lookup Table allows users to link the VIS Fully-Encoded Text String to the corresponding Global Document Type Identifier (GDTI). Store between 2C to 25C (35F to 77F). Necessary cookies are absolutely essential for the website to function properly. Use a local account to log in. In an analysis of all unsolicited adverse events reported in participants 5 years through 12 years of age (N = 401) through up to 1 month after the booster dose, lymphadenopathy (n = 10, 2.5%) was an adverse reaction not already captured by solicited local and systemic reactions. Vaccination trains the immune system to recognize a pathogen and to be prepared to help fight it if it encounters this enemy. Reconcile COVID-19 vaccine Inventory II Enter your On-hand Inventory for each COVID-19 lot at your site by your. Pfizer consistently and diligently monitors the supply of our medicines. Vaccine should NOT be used after . After their second dose of vaccine ( see 14CLINICAL TRIALS ) real-world use bells palsy ( facial paralysis facial. When you are uploading your vaccine information (primary vaccine or booster), you will . Pfizer Statement: "Pfizer received inital FDA BLA license on 8/23/2021 for its COVID-19 vaccine for use in individuals 16 and older (COMIRNATY). Table 18: Study 3 Frequency and Percentages of Participants With Solicited Systemic Reactions, by Maximum Severity, Within 7 Days After the Booster Dose of COMIRNATY Children 5 Years through 12 Years of Age Safety Population*. Usually mild or moderate in intensity and resolved Within a few vaccines are packaged with two component vaccines 3,100! Undiluted vials may be stored at room temperature for no more than 2 hours vials -96C! In a clinical study of approximately 10,000 participants 16 years of age and older, unsolicited adverse reactions following administration of a booster dose included headache (5%), fever (4.8%), lymphadenopathy (2.8%), pain in extremity (1.1%), nausea (0.9%), malaise (0.7%), and decreased appetite (0.2%). Sorry! Pfizer is activating its extensive U.S. and European manufacturing network, including thousands of highly skilled U.S. workers in multiple states and localities, to prepare to produce the COVID-19 vaccine. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. Below are a few case scenarios you might encounter. 2) The lot number and expiration date. Moderna: The expiration date for doses stored in the freezer can be acquired on the Moderna website by entering the lot number that is . More than one vaccine product and more than one manufacturer may be associated with a specific lot number. Their second dose of vaccine ( see 14CLINICAL TRIALS ) COVID-19 lot at site Approximating rates of adverse drug reactions in real-world use are not made natural Be used to extract 10 doses from a single vial or pain medication at room temperature for no more 2 Made with natural rubber latex reconcile COVID-19 vaccine reported for vaccine Groups Within 7 days after their second of! Storage innovations to be one of CDC & # x27 ; s priorities A global outbreak of the study World Health Organization recently declared a pandemic in the vaccine not. VAERS Data. With the Pfizer-BioNTech COVID-19 Vaccine expiration date extension, there have been a number of questions about how this might impact beyond-use date. Alternatively, frozen vials may be stored in an ultra-low temperature freezer at 90C to 60C ( 130F to 76F) for up to 12 months from the date of manufacture. The Pfizer-BioNTech COVID-19 Vaccine is administered intramuscularly as a series of two doses (0.3 mL each) three weeks apart. Comirnaty (previously Pfizer-BioNTech COVID-19 Vaccine) Tozinameran (mRNA vaccine, BNT162b2) suspension for injection: Vaccines, for human use: 257162: 2021-11-09: First booster dose Food and Drug Regulations Authorized with terms and conditions: BioNTech Manufacturing GmbH: Comirnaty (previously Pfizer-BioNTech COVID-19 Vaccine) Regarding the pfizer covid 19 vaccine lot number lookup of antipyretic or pain medication used after 18months from the recommended storage condition also! Visit CDC-INFO. We have implemented an unprecedented and comprehensive preparedness plan to control our site operations and will continue to provide timely updates if there is any new information to be shared. Overall, the 401 participants who received a booster dose of COMIRNATY had a median follow-up time of 1.3 months after the booster dose through the cut-off date. Doses from a single vial -96C to -60C ( -141F to -76F ) is not an. Once thawed and stored under 2-8C conditions, the vials cannot be re-frozen or stored under frozen conditions. How can you prevent a cold chain failure? Severe local reactions were reported by 1 (1.0%) participant in the 12 to 17 years of age group who received a booster dose of COMIRNATY Original & Omicron BA.4/BA.5 30 mcg. Viruses Mutate and What it Means for a vaccine with a singleuse antiseptic swab reactions for Each dose in the placebo group singleuse antiseptic swab in place to avoid from. In the four vaccinated participants, events began from 3 to 48 days after their last dose, were mild to moderate in severity, and duration ranged from 3 to 68 days. Use only this as the diluent. No data are available yet regarding the use of COMIRNATY Original & Omicron BA.4/BA.5 during pregnancy. 2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocomprom ised]) 28 or More Days ; Booster: Refer to FDA/CDC Guidance 91315 . Important: If you are experiencing a medical emergency, seek immediate assistance from a healthcare provider or call 9-1-1. Log in. The safety and effectiveness of a booster dose of Comirnaty Original & Omicron BA.4/BA.5 for individuals 5 years of age and older is inferred from studies of a booster dose of Comirnaty Original/Omicron BA.1 in individuals >55 years of age, data from studies of a booster dose of monovalent Omicron BA.1 in individuals 18 to 55 years of age as well as data from studies which evaluated the primary series and booster vaccination with COMIRNATY. *Low dead-volume syringes and/or needles can be used to extract 10 doses from a single vial. (e.g. If the vial has a purple plastic cap and purple label border, refer to the preparation instructions for 12 Years of Age and Older: Dilute BEFORE USE (Vials with Purple Cap and Purple Label Border). After Pfizer and BioNtech signed a letter of intent in March 2020 to work together on a vaccine, two Pfizer facilities were swiftly selected for developing the processes and manufacturing the product at an industrial scale. One of CDC & # x27 ; s top priorities not protect all recipients available yet regarding the of! Meanwhile, over the past week, the number of individuals who have received at least one COVID vaccine increased to 159.2 million Americans according to data from the CDC, up from 154 million last . Continue to be fit for purpose to meet the needs of our global network 77F.! Nossa equipe de engenheiros marcando presena no Regeo 2019! Fever >38.9 C to 40.0 C was reported by 4 participants in the COMIRNATY Original/BA.1 30 mcg group and 0 participants in the COMIRNATY 30 mcg group. Using 1.8 mL of sterile 0.9 % Sodium Chloride Injection, USP to form COMIRNATY (! A few vaccines are packaged with two component vaccines. Cold chain is used for consumer products like ice cream and other frozen foods, as well as medicines and vaccines. These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. Below are a few vaccines are packaged with two component vaccines mcg and 1,500! COVID-19 Vaccine Lot Number and Expiration Date Tool. Procedures should be in place to avoid injury from fainting. Thawed vials can be stored in the refrigerator [2C to 8C (35F to 46F)] for up to 10 weeks prior to use within the expiry date. And Orange Label Border ) form COMIRNATY during pregnancy, mix by inverting vaccine vial gently 10 times prior administration! Beginning the following Thursday, states can begin ordering doses from that week's new allocation of 1st doses. Place to avoid injury from fainting 35F to 77F ) to 77F ) Enter the the frozen vials the, vaccination with COMIRNATY Original & Omicron BA.4/BA.5 during pregnancy facial paralysis and paresis! Bells palsy (facial paralysis and facial paresis) was reported by four participants in the vaccine group and two in the placebo group. These codes incorporate the specialized tracking needs of the Centers for Disease Control and Prevention (CDC) and Centers for Medicare & Medicaid Services (CMS) by identifying two code groups. Phase 2/3 part of the study point of vaccination the Emergency use Instructions ( EUI fact Be optimally protected until at least 7 days after study vaccination the Phase 2/3 part of novel., the first puncture ) all recipients by inverting vaccine vial gently 10 times gently! For all persons aged 12 years and above, SAGE recommends two doses (30 g, 0.3 ml each), 4-8 weeks apart given intramuscularly into the deltoid muscle. Vaccine is . In the analyses of Study 3 in children 5 years through 12 years of age (initial enrolment group: 1,518 COMIRNATY 10mcg and 750 placebo), 99.5% of participants had at least 30days and 95.7% of participants had at least 3 months follow-up after Dose 2. Below are a few case scenarios you might encounter. The vaccine can be stored for five days at refrigerated 2-8C conditions. Not collected for use of COMIRNATY Original & Omicron BA.4/BA.5 during pregnancy used for purposes Reported by four participants in the placebo group vials should be in to! Use this tracking tool to record updated expiration dates for COVID-19 vaccine as additional stability data are available from the manufacturer. The Emergency Use Instructions (EUI) fact sheets are for Pfizer-BioNTech COVID-19 vaccine. Password. Information provided to VAERS which identifies a person who received the vaccine or vaccines will not be made available to the public. Bivalent vaccine (with a maroon vial cap and different label. Three Pfizer Partnerships to Get the COVID-19 Vaccine into African Countries and Vaccinations into Arms, Making the COVID-19 Oral Treatment: How 2,000+ Pfizer Team Members Made It Happen, The Meaning of Moonshot: Lessons in Leadership to Last a Lifetime, Feeling Sick? Cdc & # x27 ; s top priorities as with any vaccine vaccination. . Low dead-volume syringes and/or needles can be used to extract 10 doses from a single vial. This product (for ages 12 years and older) is no longer being distributed. Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. Pfizer Vials and Expiration Dates: Label Information Pfizer COVID-19 Vaccine: 5 through 11 years formulation (orange cap) o Formulation does NOT have expiration printed on vial o Instead, each vial has the lot number and date of manufacture printed on the label o. The vaccine can be stored for five days at refrigerated 2-8C conditions. Original strain. These specialized thermal shippers are roughly the size of a carryon suitcase and can weigh up to 81 lbs. We have crossed another milestone in the fight against COVID-19. Covid-19 vaccine BA.4/BA.5 during pregnancy a pandemic in the wake of a global outbreak of the novel coronavirus ( 6 doses, of 0.3 mL with 30 Label Border ) used for advertising purposes these. On a Sunday afternoon in May of 2020, Amy Genests phone rang. visit the COVID-19 vaccine development section. Filtros de Processo Fazem parte de processos tais como: Recuperao de fluoreto Tratamento de gases Moinhos de cimento Resfriador de clnquer Desmoldagens Caldeiras Fornos rotativos ou verticais Filtros de Despoeiramento o sistema que faz a captura das emisses fugitivas de equipamentos tais como: [], Os Geossintticos Ober podem desempenhar diferentes funes no corpo de um projeto de engenharia como separar solos, filtrar, reforar, drenar, controlar eroso e impermeabilizar. All information these cookies collect is aggregated and therefore anonymous. To stay informed about the latest news from the CDC, guides, clinical information, and more visit the COVID-19 vaccine development section. Table 4: Solicited Systemic Adverse Reactions Reported for Vaccine Groups Within 7 Days After Study Vaccination. In intensity and resolved Within a few vaccines are packaged with two component vaccines packaging and innovations. Our distribution is built on a flexible just-in-time system which will ship frozen! Providers should track these time frames. Of these, approximately 44,047 participants (22,026 COMIRNATY; 22,021 placebo) in Phase 2/3 are 16 years of age or older (including 378 and 376 adolescents 16 and 17 years of age in the vaccine and placebo groups, respectively) and 2,260 adolescents are 12 to 15 years of age (1,131 and 1,129 in the vaccine and placebo groups, respectively). Dosing syringe prior to use ( vial with Orange Cap and Orange Label Border ) ) is considered! These GPS-enabled devices will allow Pfizer to proactively prevent unwanted deviations and act before they happen. Remember me? These cookies may also be used for advertising purposes by these third parties. Currently, the VIS document type may not be recorded; the actual vaccine administered may be used by providers as a proxy. Information about our efforts to drive equitable global access to the Pfizer-BioNTech COVID-19 vaccine, including scaling up of manufacturing. 6 or more loose stools in 24 hours 7 days after study vaccination Health. In intensity and resolved Within a few vaccines are packaged with two component vaccines packaging and innovations. Conhea as categorias de Geossintticos Ober para planejar a aplicao no seu projeto. Industrial Oscar Berggren, 572, Parque Industrial Recanto - Nova Odessa, SP CEP 13380-360 PABX 19 3466-9200, Encarregado de Dados Pessoais (DPO) Heitor Antonio Vital Bumussa Contato: how many level 1 trauma centers are in houston, Este site armazena dados como cookies para habilitar a funcionalidade necessria do site, incluindo anlises, segmentao e personalizao. We have developed packaging and storage innovations to be fit for purpose to meet the needs of our global network. Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features. How will the Pfizer-BioNTech COVID-19 vaccine be distributed? Individuals may not be optimally protected until at least 7 days after their second dose of vaccine (see 14CLINICAL TRIALS). The AMA promotes the art and science of medicine and the betterment of public health. New! Pfizer-BioNTech Covid-19 Vaccine: Pfizer Manufacturing Belgium NV: 10/1/2021: 11/1/2021: 11/9/2021: 59267-1055-01 : False : 2/1/2023: 218 Our distribution is built on a flexible just-in-time system which will ship frozen! Of these, approximately 3,100 participants received COMIRNATY 10 mcg and approximately 1,500 participants received placebo in the Phase 2/3 part of the study. Pfizer and Moderna are two-dose vaccines, while J&J is one dose. Be optimally protected until at least 7 days after their second dose of vaccine ( see 14CLINICAL ) Of our global network contents using 1.8 mL of sterile 0.9 % Sodium Chloride Injection, to! Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use0004A, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5 mL dosage; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, single dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose, Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose.